From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute, Little Rock, AR, chairs a discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY. The experts discuss a range of topics including advanced methods of detecting and monitoring measurable residual disease (MRD), such as single cell RNA sequencing, protein-based detection in the peripheral blood using mass spectrometry, and the highly sensitive VDJ sequencing.
MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing
